Newly Published Data Further Support Mosaic ImmunoEngineering’s Lead Immuno-Oncology Candidate MIE-101 in Combination with OX40 Checkpoint Treatment in Melanoma

• Broad, durable, and systemic anti-tumor immunity observed using inCPMV with OX40 agonist antibodies
• Intratumoral inCPMV administration in combination with systemic anti-OX40 controlled the progression of the primary as well as secondary untreated tumors
• 70% of animals survived for at least 100 days post tumor challenge without development of recurrence or metastatic disease

Excerpt from the Press Release:

NOVATO, CA / ACCESSWIRE / February 2, 2022 / Mosaic ImmunoEngineering, Inc. (“Mosaic” or the “Company”), (OTCQB:CPMV), a development-stage biotechnology company focused on bridging immunology and engineering to develop novel immunotherapies to treat and prevent cancer, today announced a new article published in the journal “Molecular Pharmaceuticals.” Co-authors of the article include Mosaic co-founders Nicole F. Steinmetz, Ph.D., director of the UC San Diego Center for Nano-ImmunoEngineering, and Steven N. Fiering, Ph.D., professor of microbiology and immunology at the Geisel School of Medicine at Dartmouth University. The article, entitled, “Inactivated Cowpea Mosaic Virus in Combination with OX40 Agonist Primes Potent Antitumor Immunity in a Bilateral Melanoma Mouse Model,” details broad immune activation of inactivated CPMV (termed inCPMV) and potent, systemic, and durable antitumor activity with the treatment combination in an aggressive two-tumor model of melanoma.

“Our studies demonstrate that intratumoral administration of inCPMV and systemic administration of an OX40 agonist antibody generates potent systemic antitumor immunity,” said Dr. Steinmetz. “We observed that synergistic efficacy can be achieved through a combination of inCPMV with an OX40 agonist. InCPMV activates the innate immune system and reprograms the tumor microenvironment leading to processing of tumor-associated and neoantigens, therefore leading to adaptive anti-tumor immunity by T cells. The OX40 agonist further promotes T cell activation.”

Data showed reduced tumor burden, prolonged survival, and induced tumor antigen-specific immunologic memory to prevent relapse – most importantly, systemic activity and abscopal effect was observed in a two-tumor melanoma mouse model.

“Tumor growth was controlled over the 100-day study with 10 out of 14 animals surviving; notably the survivors were tumor-free with no palpable tumors and no signs of metastatic disease,” Steinmetz added.

Click the button below to read the entire Press Release:

Continue Reading The Press Release